Sun Pharma gets USFDA nod for Flomax's generic version

NEW DELHI: Sun Pharmaceutical Industries today said that it has received the US health regulator's nod to market a generic version of Flomax tamsulosin capsules, used for treating enlarged prostate, in the American market.

The company has bagged the Abbreviated New Drug Application approval from the US Food and Drugs Administration (USFDA) for tamsulosin hydrochloride capsules in the strength of 0.4 mg, Sun Pharma said in a statement.

The generic version launched by the company is equivalent to Boehringer Ingelheim Pharmaceuticals' patented Flomax capsules.

"Tamsulosin hydrochloride capsules are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH)," the company said.

Shares of Sun Pharma were trading at Rs 1,738.50 on the Bombay Stock Exchange, down 0.53 per cent from its previous close.